HEADER CHAPERONE 26-MAY-11 2YKE TITLE TRICYCLIC SERIES OF HSP90 INHIBITORS COMPND MOL_ID: 1; COMPND 2 MOLECULE: HEAT SHOCK PROTEIN HSP 90-ALPHA; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: N-DOMAIN, RESIDUES 18-233; COMPND 5 SYNONYM: HEAT SHOCK 86 KDA, HSP 86, HSP86, RENAL CARCINOMA ANTIGEN COMPND 6 NY-REN-38, HSP90; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21(DE3) KEYWDS CHAPERONE, INHIBITION EXPDTA X-RAY DIFFRACTION AUTHOR A.DUPUY,F.VALLEE REVDAT 3 19-APR-17 2YKE 1 REMARK REVDAT 2 02-NOV-11 2YKE 1 JRNL REVDAT 1 19-OCT-11 2YKE 0 JRNL AUTH F.VALLEE,C.CARREZ,F.PILORGE,A.DUPUY,A.PARENT,L.BERTIN, JRNL AUTH 2 F.THOMPSON,P.FERRARI,F.FASSY,A.LAMBERTON,A.THOMAS, JRNL AUTH 3 R.ARREBOLA,S.GUERIF,A.ROHAUT,V.CERTAL,J.M.RUXER,C.DELORME, JRNL AUTH 4 A.JOUANEN,J.DUMAS,C.GREPIN,C.COMBEAU,H.GOULAOUIC,N.DEREU, JRNL AUTH 5 V.MIKOL,P.MAILLIET,H.MINOUX JRNL TITL TRICYCLIC SERIES OF HEAT SHOCK PROTEIN 90 (HSP90) INHIBITORS JRNL TITL 2 PART I: DISCOVERY OF TRICYCLIC IMIDAZO[4,5-C]PYRIDINES AS JRNL TITL 3 POTENT INHIBITORS OF THE HSP90 MOLECULAR CHAPERONE. JRNL REF J.MED.CHEM. V. 54 7206 2011 JRNL REFN ISSN 0022-2623 JRNL PMID 21972823 JRNL DOI 10.1021/JM200784M REMARK 2 REMARK 2 RESOLUTION. 1.43 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER 2.9.7 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN, REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.43 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 14.35 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 93.1 REMARK 3 NUMBER OF REFLECTIONS : 51625 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.169 REMARK 3 R VALUE (WORKING SET) : 0.168 REMARK 3 FREE R VALUE : 0.185 REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : 2626 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 1.43 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 1.47 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 93.13 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : 3473 REMARK 3 BIN R VALUE (WORKING + TEST SET) : 0.2482 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 3319 REMARK 3 BIN R VALUE (WORKING SET) : 0.2465 REMARK 3 BIN FREE R VALUE : 0.2820 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 4.43 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 154 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1628 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 35 REMARK 3 SOLVENT ATOMS : 385 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 11.94 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 15.21 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 1.80960 REMARK 3 B22 (A**2) : -1.52570 REMARK 3 B33 (A**2) : -0.28390 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.138 REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : 0.058 REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : 0.058 REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : 0.053 REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : 0.054 REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.953 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.948 REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : 1695 ; 2.000 ; HARMONIC REMARK 3 BOND ANGLES : 2290 ; 2.000 ; HARMONIC REMARK 3 TORSION ANGLES : 598 ; 2.000 ; SINUSOIDAL REMARK 3 TRIGONAL CARBON PLANES : 46 ; 2.000 ; HARMONIC REMARK 3 GENERAL PLANES : 242 ; 5.000 ; HARMONIC REMARK 3 ISOTROPIC THERMAL FACTORS : 1695 ; 20.000 ; HARMONIC REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : 230 ; 5.000 ; SEMIHARMONIC REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : 2358 ; 4.000 ; SEMIHARMONIC REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.010 REMARK 3 BOND ANGLES (DEGREES) : 1.11 REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 4.11 REMARK 3 OTHER TORSION ANGLES (DEGREES) : 14.18 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2YKE COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 26-MAY-11. REMARK 100 THE PDBE ID CODE IS EBI-48453. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 19-NOV-04 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 7.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU MICROMAX-007 HF REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : AREA DETECTOR REMARK 200 DETECTOR MANUFACTURER : MAR SCANNER 345 MM PLATE REMARK 200 INTENSITY-INTEGRATION SOFTWARE : NULL REMARK 200 DATA SCALING SOFTWARE : NULL REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 51677 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.430 REMARK 200 RESOLUTION RANGE LOW (A) : 66.890 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 94.1 REMARK 200 DATA REDUNDANCY : 4.000 REMARK 200 R MERGE (I) : 0.03000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.43 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.51 REMARK 200 COMPLETENESS FOR SHELL (%) : 91.7 REMARK 200 DATA REDUNDANCY IN SHELL : 3.50 REMARK 200 R MERGE FOR SHELL (I) : 0.18000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 61.47 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.19 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PH 7.5 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: I 2 2 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z REMARK 290 3555 -X,Y,-Z REMARK 290 4555 X,-Y,-Z REMARK 290 5555 X+1/2,Y+1/2,Z+1/2 REMARK 290 6555 -X+1/2,-Y+1/2,Z+1/2 REMARK 290 7555 -X+1/2,Y+1/2,-Z+1/2 REMARK 290 8555 X+1/2,-Y+1/2,-Z+1/2 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 5 1.000000 0.000000 0.000000 33.22000 REMARK 290 SMTRY2 5 0.000000 1.000000 0.000000 45.43500 REMARK 290 SMTRY3 5 0.000000 0.000000 1.000000 49.41000 REMARK 290 SMTRY1 6 -1.000000 0.000000 0.000000 33.22000 REMARK 290 SMTRY2 6 0.000000 -1.000000 0.000000 45.43500 REMARK 290 SMTRY3 6 0.000000 0.000000 1.000000 49.41000 REMARK 290 SMTRY1 7 -1.000000 0.000000 0.000000 33.22000 REMARK 290 SMTRY2 7 0.000000 1.000000 0.000000 45.43500 REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 49.41000 REMARK 290 SMTRY1 8 1.000000 0.000000 0.000000 33.22000 REMARK 290 SMTRY2 8 0.000000 -1.000000 0.000000 45.43500 REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 49.41000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 15 REMARK 465 HIS A 16 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O HOH A 2365 O HOH A 2366 2.17 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASN A 105 -63.95 -102.99 REMARK 500 ALA A 166 -148.42 64.69 REMARK 500 ARG A 182 144.99 -170.55 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE YKE A 1224 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2YI0 RELATED DB: PDB REMARK 900 STRUCTURAL CHARACTERIZATION OF 5-ARYL-4-(5-SUBSTITUTED- 2-4- REMARK 900 DIHYDROXYPHENYL)-1,2,3-THIADIAZOLE HSP90 INHIBITORS. REMARK 900 RELATED ID: 2YK9 RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 1OSF RELATED DB: PDB REMARK 900 HUMAN HSP90 IN COMPLEX WITH 17-DESMETHOXY-17-N,N- REMARK 900 DIMETHYLAMINOETHYLAMINO-GELDANAMYCIN REMARK 900 RELATED ID: 2BSM RELATED DB: PDB REMARK 900 NOVEL, POTENT SMALL MOLECULE INHIBITORS OF THE MOLECULAR CHAPERONE REMARK 900 HSP90 DISCOVERED THROUGH STRUCTURE-BASED DESIGN REMARK 900 RELATED ID: 2WI3 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 REMARK 900 CHAPERONE REMARK 900 RELATED ID: 2YE4 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2YI5 RELATED DB: PDB REMARK 900 STRUCTURAL CHARACTERIZATION OF 5-ARYL-4-(5-SUBSTITUTED- 2-4- REMARK 900 DIHYDROXYPHENYL)-1,2,3-THIADIAZOLE HSP90 INHIBITORS. REMARK 900 RELATED ID: 2YE5 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2BZ5 RELATED DB: PDB REMARK 900 STRUCTURE-BASED DISCOVERY OF A NEW CLASS OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2CCS RELATED DB: PDB REMARK 900 HUMAN HSP90 WITH 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H- PYRAZOL-3-YL)- REMARK 900 BENZENE-1,2-DIOL REMARK 900 RELATED ID: 2YEI RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2YEG RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 1UYI RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2,5-DIMETHOXY-BENZYL)-2- FLUORO-9-PENT-9H- REMARK 900 PURIN-6-YLAMINE REMARK 900 RELATED ID: 1YC3 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN HSP90ALPHA COMPLEXED REMARK 900 WITHDIHYDROXYPHENYLPYRAZOLES REMARK 900 RELATED ID: 1UYF RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2-CHLORO-3,4,5- TRIMETHOXY-BENZYL)-2- REMARK 900 FLUORO-9-PENT-4-YLNYL-9H-PURIN -6-YLAMINE REMARK 900 RELATED ID: 2YE3 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2BYI RELATED DB: PDB REMARK 900 3-(5-CHLORO-2,4-DIHYDROXYPHENYL)-PYRAZOLE-4- CARBOXAMIDES AS REMARK 900 INHIBITORS OF THE HSP90 MOLECULAR CHAPERONE REMARK 900 RELATED ID: 2YI6 RELATED DB: PDB REMARK 900 STRUCTURAL CHARACTERIZATION OF 5-ARYL-4-(5-SUBSTITUTED- 2-4- REMARK 900 DIHYDROXYPHENYL)-1,2,3-THIADIAZOLE HSP90 INHIBITORS. REMARK 900 RELATED ID: 2VCI RELATED DB: PDB REMARK 900 4,5 DIARYL ISOXAZOLE HSP90 CHAPERONE INHIBITORS: POTENTIAL REMARK 900 THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER REMARK 900 RELATED ID: 2WI1 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 REMARK 900 CHAPERONE REMARK 900 RELATED ID: 2XJX RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2FWZ RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN HSP90-ALPHA BOUND TO THE POTENT WATERSOLUBLE REMARK 900 INHIBITOR PU-H71 REMARK 900 RELATED ID: 2XDK RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XJG RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 1UYH RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2,5-DIMETHOXY- BENZYL)-2-FLUORO- REMARK 900 9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 2FWY RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN HSP90-ALPHA BOUND TO THE POTENT WATERSOLUBLE REMARK 900 INHIBITOR PU-H64 REMARK 900 RELATED ID: 1UYE RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2-CHLORO-3,4,5- TRIMETHOXY-BENZYL)-9-PENT- REMARK 900 4-YLNYL-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UYL RELATED DB: PDB REMARK 900 STRUCTURE-ACTIVITY RELATIONSHIPS IN PURINE-BASED INHIBITOR BINDING REMARK 900 TO HSP90 ISOFORMS REMARK 900 RELATED ID: 2XAB RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH AN INHIBITOR BOUND REMARK 900 RELATED ID: 2YEH RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 1UY7 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(4-METHOXY-BENZYL )-9H-PURIN-6- REMARK 900 YLAMINE REMARK 900 RELATED ID: 2XHT RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XHR RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2YEF RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2BYH RELATED DB: PDB REMARK 900 3-(5-CHLORO-2,4-DIHYDROXYPHENYL)-PYRAZOLE-4- CARBOXAMIDES AS REMARK 900 INHIBITORS OF THE HSP90 MOLECULAR CHAPERONE REMARK 900 RELATED ID: 2WI5 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 REMARK 900 CHAPERONE REMARK 900 RELATED ID: 2CDD RELATED DB: PDB REMARK 900 HUMAN HSP90 WITH 4-(4-(2,3-DIHYDRO-BENZOL(1,4) DIOXIN-6-YL)-5- REMARK 900 METHYL-1H-PYRAZOL-3-YL)-6-ETHYL- BENZENE-1,3-DIOL REMARK 900 RELATED ID: 1UY9 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-BENZO[1,3]DIOXOL-,5- YLMETHYL-9-BUTYL-9H- REMARK 900 PURIN-6-YLAMINE REMARK 900 RELATED ID: 1YES RELATED DB: PDB REMARK 900 HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, "OPEN" CONFORMATION REMARK 900 RELATED ID: 1BYQ RELATED DB: PDB REMARK 900 HSP90 N-TERMINAL DOMAIN BOUND TO ADP-MG REMARK 900 RELATED ID: 2YI7 RELATED DB: PDB REMARK 900 STRUCTURAL CHARACTERIZATION OF 5-ARYL-4-(5-SUBSTITUTED- 2-4- REMARK 900 DIHYDROXYPHENYL)-1,2,3-THIADIAZOLE HSP90 INHIBITORS. REMARK 900 RELATED ID: 1UY8 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(3-TRIMETHOXY- BENZYL)-9H-PURIN- REMARK 900 6YLAMINE REMARK 900 RELATED ID: 2WI4 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 REMARK 900 CHAPERONE REMARK 900 RELATED ID: 2BUG RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE TPR DOMAIN FROM PROTEIN PHOSPHATASE 5 IN REMARK 900 COMPLEX WITH HSP90 DERIVED PEPTIDE REMARK 900 RELATED ID: 2UWD RELATED DB: PDB REMARK 900 INHIBITION OF THE HSP90 MOLECULAR CHAPERONE IN VITRO AND IN VIVO BY REMARK 900 NOVEL, SYNTHETIC, POTENT RESORCINYLIC PYRAZOLE, ISOXAZOLE AMIDE REMARK 900 ANALOGS REMARK 900 RELATED ID: 2YEB RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2YE7 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2XHX RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2YKC RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2WI7 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 REMARK 900 CHAPERONE REMARK 900 RELATED ID: 2YEJ RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2BT0 RELATED DB: PDB REMARK 900 NOVEL, POTENT SMALL MOLECULE INHIBITORS OF THE MOLECULAR CHAPERONE REMARK 900 HSP90 DISCOVERED THROUGH STRUCTURE-BASED DESIGN REMARK 900 RELATED ID: 1YER RELATED DB: PDB REMARK 900 HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, "CLOSED" CONFORMATION REMARK 900 RELATED ID: 2XDU RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2YEC RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 1UYG RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2,5-DIMETHOXY-BENZYL)-2- FLUORO-9H-PURIN- REMARK 900 6-YLAMINE REMARK 900 RELATED ID: 2CCU RELATED DB: PDB REMARK 900 HUMAN HSP90 WITH 4-CHLORO-6-(4-(4-(4- METHANESULPHONYL-BENZYL)- REMARK 900 PIERAZIN-1-YL)-1H-PYRAZOL-3- YL)-BENZENE-1,3-DIOL REMARK 900 RELATED ID: 2XDS RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XDX RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XK2 RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XJJ RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 1UYD RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2-CHLORO-3,4,5 -TRIMETHOXY-BENZYL) REMARK 900 -9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 2XDL RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2WI2 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 REMARK 900 CHAPERONE REMARK 900 RELATED ID: 1UY6 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(3,4,5-TRIMETHOXY -BENZYL)-9H- REMARK 900 PURIN-6-YLAMINE REMARK 900 RELATED ID: 2YEE RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2YE2 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2VCJ RELATED DB: PDB REMARK 900 4,5 DIARYL ISOXAZOLE HSP90 CHAPERONE INHIBITORS: POTENTIAL REMARK 900 THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER REMARK 900 RELATED ID: 1YC4 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN HSP90ALPHA COMPLEXED REMARK 900 WITHDIHYDROXYPHENYLPYRAZOLES REMARK 900 RELATED ID: 2YE9 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2C2L RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE CHIP U-BOX E3 UBIQUITIN LIGASE REMARK 900 RELATED ID: 1UYK RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-BENZO[1,3]DIOXOL-,5- YLMETHYL-9-BUTYL-2- REMARK 900 FLUORO-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 2CCT RELATED DB: PDB REMARK 900 HUMAN HSP90 WITH 5-(5-CHLORO-2,4-DIHYDROXY-PHENYL)- 4-PIPERAZIN-1- REMARK 900 YL-2H-PYRAZOLE-3-CARBOXYLIC ACID ETHYLAMIDE REMARK 900 RELATED ID: 2YK2 RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2WI6 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 REMARK 900 CHAPERONE REMARK 900 RELATED ID: 1YC1 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURES OF HUMAN HSP90ALPHA COMPLEXED REMARK 900 WITHDIHYDROXYPHENYLPYRAZOLES REMARK 900 RELATED ID: 2YEA RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2YE6 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2YED RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 1UYC RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2,5-DIMETHOXY- BENZYL)-9H-PURIN-6- REMARK 900 YLAMINE REMARK 900 RELATED ID: 1YET RELATED DB: PDB REMARK 900 GELDANAMYCIN BOUND TO THE HSP90 GELDANAMYCIN-BINDING DOMAIN REMARK 900 RELATED ID: 2JJC RELATED DB: PDB REMARK 900 HSP90 ALPHA ATPASE DOMAIN WITH BOUND SMALL MOLECULE FRAGMENT REMARK 900 RELATED ID: 2YJX RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2YE8 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2YKB RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2YKI RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2YKJ RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS DBREF 2YKE A 18 223 UNP P07900 HS90A_HUMAN 18 223 SEQADV 2YKE GLY A 15 UNP P07900 EXPRESSION TAG SEQADV 2YKE HIS A 16 UNP P07900 EXPRESSION TAG SEQADV 2YKE MET A 17 UNP P07900 EXPRESSION TAG SEQRES 1 A 209 GLY HIS MET GLU THR PHE ALA PHE GLN ALA GLU ILE ALA SEQRES 2 A 209 GLN LEU MET SER LEU ILE ILE ASN THR PHE TYR SER ASN SEQRES 3 A 209 LYS GLU ILE PHE LEU ARG GLU LEU ILE SER ASN SER SER SEQRES 4 A 209 ASP ALA LEU ASP LYS ILE ARG TYR GLU SER LEU THR ASP SEQRES 5 A 209 PRO SER LYS LEU ASP SER GLY LYS GLU LEU HIS ILE ASN SEQRES 6 A 209 LEU ILE PRO ASN LYS GLN ASP ARG THR LEU THR ILE VAL SEQRES 7 A 209 ASP THR GLY ILE GLY MET THR LYS ALA ASP LEU ILE ASN SEQRES 8 A 209 ASN LEU GLY THR ILE ALA LYS SER GLY THR LYS ALA PHE SEQRES 9 A 209 MET GLU ALA LEU GLN ALA GLY ALA ASP ILE SER MET ILE SEQRES 10 A 209 GLY GLN PHE GLY VAL GLY PHE TYR SER ALA TYR LEU VAL SEQRES 11 A 209 ALA GLU LYS VAL THR VAL ILE THR LYS HIS ASN ASP ASP SEQRES 12 A 209 GLU GLN TYR ALA TRP GLU SER SER ALA GLY GLY SER PHE SEQRES 13 A 209 THR VAL ARG THR ASP THR GLY GLU PRO MET GLY ARG GLY SEQRES 14 A 209 THR LYS VAL ILE LEU HIS LEU LYS GLU ASP GLN THR GLU SEQRES 15 A 209 TYR LEU GLU GLU ARG ARG ILE LYS GLU ILE VAL LYS LYS SEQRES 16 A 209 HIS SER GLN PHE ILE GLY TYR PRO ILE THR LEU PHE VAL SEQRES 17 A 209 GLU HET YKE A1224 35 HETNAM YKE N-[(4R)-4-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-4H-FLUOREN-9- HETNAM 2 YKE YL]QUINOLINE-5-CARBOXAMIDE FORMUL 2 YKE C29 H19 N5 O FORMUL 3 HOH *385(H2 O) HELIX 1 1 GLN A 23 THR A 36 1 14 HELIX 2 2 GLU A 42 ASP A 66 1 25 HELIX 3 3 PRO A 67 ASP A 71 5 5 HELIX 4 4 THR A 99 ASN A 105 1 7 HELIX 5 5 ASN A 105 GLY A 125 1 21 HELIX 6 6 ASP A 127 GLY A 135 5 9 HELIX 7 7 VAL A 136 LEU A 143 5 8 HELIX 8 8 GLU A 192 LEU A 198 5 7 HELIX 9 9 GLU A 199 SER A 211 1 13 SHEET 1 AA 8 GLU A 18 ALA A 21 0 SHEET 2 AA 8 SER A 169 THR A 174 -1 O PHE A 170 N PHE A 20 SHEET 3 AA 8 TYR A 160 SER A 164 -1 O ALA A 161 N ARG A 173 SHEET 4 AA 8 ALA A 145 LYS A 153 -1 O VAL A 148 N SER A 164 SHEET 5 AA 8 GLY A 183 LEU A 190 -1 O GLY A 183 N LYS A 153 SHEET 6 AA 8 THR A 88 ASP A 93 -1 O LEU A 89 N LEU A 188 SHEET 7 AA 8 ILE A 78 ASN A 83 -1 O ASN A 79 N VAL A 92 SHEET 8 AA 8 ILE A 218 LEU A 220 1 O THR A 219 N LEU A 80 SITE 1 AC1 17 ASN A 51 ALA A 55 ASP A 93 MET A 98 SITE 2 AC1 17 LEU A 103 ILE A 104 LEU A 107 GLY A 108 SITE 3 AC1 17 GLY A 135 TYR A 139 TRP A 162 PHE A 170 SITE 4 AC1 17 THR A 184 HOH A2012 HOH A2120 HOH A2121 SITE 5 AC1 17 HOH A2232 CRYST1 66.440 90.870 98.820 90.00 90.00 90.00 I 2 2 2 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.015051 0.000000 0.000000 0.00000 SCALE2 0.000000 0.011005 0.000000 0.00000 SCALE3 0.000000 0.000000 0.010119 0.00000 MASTER 491 0 1 9 8 0 5 6 0 0 0 17 END